Skip to main content
Terug
Watch Compare

NORTHWEST BIOTHERAPEUTICS INC

Datakwaliteit: 100%
NWBO
OTC Manufacturing Chemicals
€ 0,20
€ 0,00 (0,00%)
Marktkapitalisatie: 308,14 M
Prijs
€ 0,20
Marktkapitalisatie
308,14 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue grew 1,72% annually over 5 years — modest growth
Negative free cash flow of -49,84 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 30,19%

Groei

Revenue Growth (5Y)
1,72%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)-28,47%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net Margin-9580,90%
Op. Margin-6927,32%

Veiligheid

Debt / Equity
N/A
Current Ratio0,08
Interest Coverage-7,60

Waardering

PE (TTM|NTM)
-3,43 | -3,98
Onder sectorgemiddelde (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1366 peers)
Metriek Aandeel Sector Mediaan
P/E -3,4 -1,5
P/B — 1,6
ROE % — -53,5
Net Margin % -9580,9 -41,5
Rev Growth 5Y % 1,7 1,8
D/E — 0,3

Koersdoel Analisten

1 analist
Strong Buy
Huidig
€ 0,20
+400.0%
Koersdoel
€ 1,00
€ 1,00
€ 1,00
€ 1,00
Vooruitzicht
Forward K/W -4,00
Forward WPA -€ 0,05
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2026 -€ 0,05
-€ 0,05 – -€ 0,05
 0,0 1

All Fundamental Metrics
Growth
Revenue Growth (1Y) -28,47% Revenue Growth (3Y) -9,38%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 1,72% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 937.000,0 Net Income (TTM) -89,77 M
ROE N/A ROA -298,47%
Gross Margin N/A Operating Margin -6927,32%
Net Margin -9580,90% Free Cash Flow (TTM) -49,84 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,08
Interest Coverage -7,60 Asset Turnover 0,03
Working Capital -80,71 M Tangible Book Value -109,27 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3,43 Forward P/E -3,98
P/B Ratio N/A P/S Ratio 328,85
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -16,18%
Market Cap 308,14 M Enterprise Value 375,78 M
Per Share
EPS (Diluted TTM) -0,06 Revenue / Share 0,00
FCF / Share -0,03 OCF / Share -0,03
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 55,52%
SBC-Adj. FCF N/A Growth Momentum -30,19

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 1,38 M 1,93 M 1,68 M 1,01 M 1,29 M
Net Income -83,78 M -62,60 M -105,03 M 179,13 M -529,82 M
EPS (Diluted) -0,07 -0,06 -0,10 -0,06 —
Gross Profit — — — — —
Operating Income -66,51 M -55,51 M -67,18 M -52,70 M -86,61 M
EBITDA — — — — —
R&D Expenses 34,89 M 27,73 M 35,51 M 20,31 M 33,64 M
SG&A Expenses — — — — —
D&A 1,74 M 1,53 M 1,25 M 324.000,0 87.000,0
Interest Expense 7,77 M 5,24 M 6,07 M 5,01 M 8,54 M
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 26,73 M 27,87 M 31,32 M 40,16 M 32,90 M
Total Liabilities 105,71 M 74,92 M 136,37 M 164,15 M 395,85 M
Shareholders' Equity -94,49 M -65,77 M -128,10 M -123,99 M -362,95 M
Total Debt 62,68 M 40,79 M 21,59 M 32,46 M 14,84 M
Cash & Equivalents 2,18 M 2,13 M 6,97 M 15,17 M 9,98 M
Current Assets 4,06 M 4,13 M 9,43 M 17,29 M 15,51 M
Current Liabilities 68,27 M 45,20 M 126,01 M 133,77 M 382,42 M